R&D

Pipeline

HOME  >  R&D  >  Pipeline

The problem and market of NASH

The problem

문제점

The market

시장현황

The mechanism of other developed agents
1. act on PPARα/δ-non PPARγ, decrease lipid level in plasma, phase III
2. act on the receptor (FXR) of biosynthesis of cholic acid, increase LDL, phase III
3. Inhibitor of Stearoyl-CoA desaturase 1. Inhibition of lipid deposition in fatty liver, phase II (holding state)

NIBEC solution for NASH/NAFLD

  • Derivatives of NIPEP-CARE by amino acid substitution
  • The peptide significantly arrests the expression of NASH marker
  • The peptide has additional novel target that DISSOLVE FIBROSIS
  • Modulate hepatic cell reprogramming
  • Decrease the liver hypertrophy and fat deposition
  • Advantageous to universal therapeutic efficacy to NASH from indication driven by diabetes, obesity, MCD (works all type of NASH MODEL)
  • Current status: Preclinical efficacy, MOA
  • Administration route: Injection, Oral formulation

Recovery of the MCD mouse liver treated by NIPEP-CARE


Immunohistochemistry of α-SMA and HE staining : Dissolution of fibrosis by the peptide